Community pharmacy could play an important role in proactive detection of heart valve disease (HVD), which remains under-recognised and under-detected in
England, suggested a new report published by Wilmington Healthcare.
Pharmacy bodies, including Royal Pharmaceutical Society (RPS), National Pharmacy Association (NPA) and Community Pharmacy England (CPE), have also endorsed the
report, which encourages Integrated Care Boards (ICBs) to consider the innovative approach of detecting HVD with the help of community pharmacists.
Despite HVD detection being a priority listed in the NHS Long Term Plan, a large number of people with HVD remained undiagnosed and untreated in the country due
to lack of awareness of the disease prevalence.
In June 2022, a pilot study was launched in Farnborough Primary Care Network (PCN), Hampshire, to evaluate the feasibility of using e-stethoscopes
(digital auscultation) to detect this heart condition by a community pharmacist.